Pipeline

Meinox rolls out four product pipelines, aiming at large, global, and unmet needs. We are focusing our product pipeline on two distinct indications: Cancer (prostate, pancreas, leukemia) and obesity/diabetes.​ While these two indications may seem a world apart, excellent targets have been identified in both areas of disease, opening up the possibility to leverage our technology to its full potential. 

We are looking for strategic partnerships and VC investment towards in GMP grade API synthesis, pre-formulation and preclinical validations.​

Technology

​Meinox Pharma Technologies, founded by Associate Professor Dr. Fatih Kocabas, is developing new pharmaceutical technologies for various cancers and malignancies. Meisinib™ (a new version of MEIS inhibitor based on our MEISi-EX™ technology) is a druggable target-based small molecule, developed and validated by Meinox. Meisinib is Meinox's first innovative pharmaceutical product. Meisinib™ inhibits cardiovascular, diabetes and obesity-related MEIS proteins, which play a critical role in cell and cancer metabolism. The most important benefit it offers to the pharmaceutical R & D sector is to provide tools for modulating the molecular mechanisms of these diseases. Meisinib™ stands out with the potential to offer personalized treatment in medical and veterinary applications.
 
Meisinib™ was developed by in silico drug screening; and validated by in vitro luciferase assays; PCR pathway analyses; cancer cell viability assays, apoptosis assays, ex vivo HSC expansion studies and in vivo HSC expansion studies, and in vivo gene expression analysis.
 
In a nutshell, Meisinib™ comes forth as a new small molecule opening up new basic research horizons and providing new drug development opportunities. It is a drug candidate taking into account patient’s quality of life and related health expenditures.

Applications

Meisinib™ has specificity and selectivity for MEIS proteins. It could provide a targeted therapy to patients by distinguishing between MEIS+ cancer types and disease-causing oncogene.  Using Meisinib™ on MEIS+ phenotype patients may increase the success of personalized treatment. Meisinib™ is designed to have non-cardiotoxic properties, which is an important side effect of conventional chemotherapies.
  • Meisinib™ could be used in the treatment of over 200 different cancers, its given that it has MEIS expression
  • MEIS proteins act as transcription factors and mostly involved in development and cancer and cooporates with HOXA9 and PBX1-3.
  • MEIS1-3 ant its cofactors PBX1-3 and HoxA9 are especially upregulated in thymoma, pancreatic adenocarcinoma, glioma glioblastoma and leukemia/lymphoma compared to healthy counterparts.
Other potential uses of Meisinib™
​NCDs (noncommunicable diseases, including CVDs, diabetes and cancer) present difficult challenges as the subject of basic research activities towards understanding their progression and biology. In order to improve the early detection and treatment procedures with targeted drugs, the pharmaceutical industry needs new molecular agents that can exploit the genetic and molecular dependencies of the NCDs.
 
MEIS proteins are proven to be highly associated with diseases such as diabetes, obesity and CVDs which makes Meisinib™ a drug candidate for these diseases. Preliminary studies suggest that removed MEIS protein in animal models may prevent high-fat induces obesity and type 2 diabetes. Studies also show that MEIS is an integral part of the transcriptional network that regulates cardiomyocyte cell cycle and stem cell maintenance as well . Therefore newly developed Meisinib™ could be a pivotal tool for the induction of cardiac regeneration as well as improvements in the treatment of bone marrow transplants and anemias.